A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers.
Sela I, Lahav C, Lowenthal G, Harel M, Elon Y, Yellin B, Dicker A, Halaban R, Marte J, Sznol M, Gulley J. A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers. Journal Of Clinical Oncology 2024, 42: 2568-2568. DOI: 10.1200/jco.2024.42.16_suppl.2568.Peer-Reviewed Original ResearchNon-small cell lung cancerHPV-related cancersProgression-free survivalPre-treatment plasma samplesInhibitor-based therapySquamous cell carcinomaPD-(L)1Overall survivalCell carcinomaCancer typesClinical benefitImmune checkpoint inhibitor (ICI)-based therapyMetastatic non-small cell lung cancerHead and neck squamous cell carcinomaAnogenital squamous cell carcinomasHazard ratioPD-1 inhibitor monotherapyNeck squamous cell carcinomaMultivariate Cox proportional hazards modelPredicting clinical benefitImmune checkpoint inhibitorsECOG performance statusInhibitor combination therapyPlasma samplesKaplan-Meier method